Preliminary results from FLAGSHP-1: A phase 1 study of ERAS-601 as a monotherapy or in combination with cetuximab in patients (pts) previously treated for advanced chordoma.

被引：0
|
作者：
Gounder, Mrinal M.
Rosen, Ezra
Parikh, Aparna Raj
Conley, Anthony Paul
Hong, David S.
Sheth, Siddharth
Mai, Nicholas
Sgroe, Erica
Mitchell, Ryan
Picard, Roxana
Brail, Les H.
Cote, Gregory Michael
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Harvard Med Sch, Massachusetts Gen Hosp, Div Hematol & Oncol, Dept Med, Boston, MA USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[4] Univ N Carolina, Chapel Hill, NC USA
[5] Erasca Inc, San Diego, CA USA
[6] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11522
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase 1/2 study of ramucirumab plus nivolumab in patients with previously treated advanced gastric adenocarcinoma
    Shoji, H.
    Miyamoto, H.
    Hara, H.
    Takahari, D.
    Machida, N.
    Esaki, T.
    Nagashima, K.
    Aoki, K.
    Honda, K.
    Nagata, Y.
    Miyamoto, T.
    Boku, N.
    Kato, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [22] PHASE 1/2 STUDY OF THOR-707 (SAR444245), A PEGYLATED RECOMBINANT NON-ALPHA IL-2, AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB OR CETUXIMAB IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS
    Falchook, Gerald
    Gan, Hui
    Fu, Siqing
    McKean, Meredith
    Azad, Arun
    Sommerhalder, David
    Wang, Judy
    Tan, Tira
    Chee, Chen
    Barve, Minal
    Lemeque, Charlotte
    Acuff, Nicole
    Pham, Helene
    Mooney, Jill
    Wang, Rui
    Marina, Neyssa
    Abbadessa, Giovanni
    Meniawy, Tarek
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A511 - A511
  • [23] Preliminary Results from an Ongoing Phase 1/2 Study of INCB057643, a Bromodomain and Extraterminal (BET) Protein Inhibitor, in Patients (pts) with Advanced Malignancies
    Forero-Torres, Andres
    Rosen, Seth
    Smith, David C.
    Lesser, Glenn
    Peguero, Julio
    Gupta, Shilpa
    Watts, Justin M.
    Noel, Marcus
    Kurzrock, Razelle
    Park, Haeseong
    LoRusso, Patricia
    Coombs, Catherine C.
    Zheng, Fred
    Switzky, Julie
    Yeleswaram, Swamy
    Falchook, Gerald
    BLOOD, 2017, 130
  • [24] A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in pts with NSCLC previously treated with platinum-based chemotherapy: Results of Okayama Lung Cancer Study Group (OLCSG) trial 0503
    Segawa, Y.
    Hotta, K.
    Takigawa, N.
    Matsuo, K.
    Yoshioka, H.
    Hayashi, H.
    Nogami, N.
    Tabata, M.
    Kiura, K.
    Tanimoto, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [25] A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results
    Segal, Neil Howard
    Girda, Eugenia
    Sohal, Davendra
    Lakhani, Nehal J.
    Olszanski, Anthony J.
    Fong, Lawrence
    Kinnaman, Michael David
    Han, Hyunsil
    Skokos, Dimitris
    Casey, Kerry A.
    Wang, JuAn
    Wang, Bei
    Hao, Yi
    Li, Siyu
    Ganguly, Samit
    Lowy, Israel
    Seebach, Frank A.
    Mathias, Melissa Divya
    Johnson, Melissa Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma
    Gibney, Geoffrey Thomas
    Hamid, Omid
    Gangadhar, Tara C.
    Lutzky, Jose
    Olszanski, Anthony J.
    Gajewski, Thomas
    Chmlelowski, Bartosz
    Boasberg, Peter D.
    Zhao, Yufan
    Newton, Robert Charles
    Scherle, Peggy A.
    Bowman, Jill
    Maleski, Janet
    Leopold, Lance
    Weber, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] Preliminary results from fight-102: a phase 1 study of pemigatinib in Japanese patients with advanced malignancies
    Kuboki, Yasutoshi
    Furukawa, Masayuki
    Takahashi, Yasuo
    Mizuno, Nobumasa
    Hara, Hiroki
    Ueno, Makoto
    Ioka, Tatsuya
    Takahashi, Shunji
    Shimizu, Toshio
    Lihou, Christine F.
    Tian, Chenwei
    Ji, Tao
    Fujiwara, Yutaka
    ANNALS OF ONCOLOGY, 2019, 30
  • [28] Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study
    Lonardi, Sara
    Prete, Alessandra Anna
    Morano, Federica
    Messina, Marco
    Formica, Vincenzo
    Corsi, Domenico Cristiano
    Orciuolo, Corrado
    Frassineti, Giovanni Luca
    Zampino, Maria Giulia
    Casagrande, Mariaelena
    Masi, Gianluca
    Ronzoni, Monica
    Scartozzi, Mario
    Buonadonna, Angela
    Mosconi, Stefania
    Ratti, Margherita
    Sartore-Bianchi, Andrea
    Tamburini, Emiliano
    Prisciandaro, Michele
    Bergamo, Francesca
    Spada, Massimiliano
    Corallo, Salvatore
    Vettore, Valentina
    Loupakis, Fotios
    Fassan, Matteo
    Del Bianco, Paola
    Zagonel, Vittorina
    Pietrantonio, Filippo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (11)
  • [29] A phase 1 study of ABX196 in combination with nivolumab in patients with previously treated hepatocellular carcinoma (HCC)
    Sigal, Darren
    Bhangoo, Munveer Singh
    Frenette, Catherine T.
    Lee, Sunyoung S.
    Fark, Christine
    Gineste, Paul
    Vissian, Anais
    Teyton, Luc
    Pearce, Tillman E.
    Kaseb, Ahmed Omar
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [30] Combination of Asciminib plus Nilotinib or Asciminib plus Dasatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results
    DeAngelo, Daniel J.
    Mauro, Michael J.
    Kim, Dong-Wook
    Cortes, Jorge
    Rea, Delphine
    Hughes, Timothy P.
    Minami, Hironobu
    Breccia, Massimo
    Talpaz, Moshe
    Hochhaus, Andreas
    Goh, Yeow Tee
    Le Coutre, Philipp D.
    Sondhi, Manu
    Mishra, Kaushal
    Hourcade-Potelleret, Florence
    Vanasse, Gary
    Aimone, Paola
    Lang, Fabian
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S290 - S291
12345